no-indomethacin

NO-indomethacin is a hybrid molecule of indomethacin and a nitric oxide (NO) donor. This drug design combines the anti-inflammatory properties of a non-steroidal anti-inflammatory drug (NSAID) with the gastrointestinal protective effects of NO. Compounds of this class retain their anti-inflammatory and analgesic activity, but have reduced gastrointestinal and kidney toxicity compared to the NSAID alone. NO-indomethacin also enhances the cancer chemopreventative activity of indomethacin. NO-indomethacin exhibits an IC50 of 82 μM, compared to >1,000 μM for indomethacin alone, for the inhibition of pancreatic cancer cell (PaCa-2) growth after 24 hours in culture.

COX-2-IN-51 (E25) 是一种高效的COX-2抑制剂，IC50为70.7 nM。它显著抑制LPS诱导的NO和PGE2释放，并减少COX-2和iNOS的表达，以及抑制NF-κB通路激活。在多种小鼠模型中，通过抑制NF-κB通路，COX-2-IN-51展示了抗炎和镇痛特性。此外，其胃肠道副作用比Indomethacin更低。

Tinoridine hydrochloride (Y-3642 hydrochloride) 是非甾体抗炎药，具有显著的自由基清除和抗过氧化物特性。